CALR and myeloproliferative disorder: Therapeutic cancer vaccination with a peptide derived from CALR exon 9 mutations, or the mutant-CALR peptide vaccine combined with keyhole limpet hemocyanin and poly-ICLC, can induce strong cellular immune responses in patients with CALR-mutant MPN.